CVI Holdings’s Zevra Therapeutics ZVRA Stock Holding History

CVI Holdings’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-244,274	Closed	-$3.13M	–	928
2021 Q2	$3.13M	Buy	+244,274	New	+$2.63M	0.21%	158

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CVI Holdings's ZVRA Position: Q3 2021 in Review

CVI Holdings sold out of Zevra Therapeutics (ZVRA) in Q3 2021, closing a stake of 244,274 shares — an estimated $3.13M sold.

CVI Holdings first reported a position in ZVRA in Q2 2021 and held it in 1 quarter. The position peaked at $3.13M in Q2 2021. 71 funds tracked by Wall St. Rank hold ZVRA as of Q3 2021.

CVI Holdings reported no remaining Zevra Therapeutics position as of Q3 2021 after selling out during the quarter.
CVI Holdings sold 244,274 Zevra Therapeutics shares in Q3 2021, an estimated $3.13M.
CVI Holdings first reported a position in Zevra Therapeutics in Q2 2021 and held it in 1 quarter.
CVI Holdings's Zevra Therapeutics position peaked at $3.13M in Q2 2021.
71 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2021.

Based on CVI Holdings's 13F filing for Q3 2021, filed 15 Nov 2021.